Abstract
About this talk
Medicinal plants represent an important source of biologically active compounds with applications in biotechnology, phytopharmacology, and pharmaceutical development. However, integrating botanical characteristics, phytochemical biosynthesis, molecular mechanisms, pharmacokinetics, and drug-delivery processes within a consistent mathematical architecture remains challenging. I present the Bansal B-PhytoPharma Framework, a unified nonlinear mathematical approach connecting medicinal-plant biology, biochemical transformations, phytopharmacological responses, and nano-drug delivery through explicitly defined computational relationships. The framework incorporates my four proposed mathematical foundations, Bansal F1–F4. F1 establishes stratified-layer mathematical representations, admissibility conditions, and physical observable recovery. F2 formulates coupled nonlinear governing equations describing biochemical reactions, molecular transport, metabolic transformations, and physiological responses. F3 addresses constrained statistical inference, parameter identification, and uncertainty estimation. F4 introduces a variational–tensor numerical formulation with graded mechanism-sensitive residual contributions. Together, these foundations provide mathematical interfaces for connecting botanical processes to phytochemical production and subsequent pharmacological behaviour while preserving classical mathematical restrictions and conservation principles. Within the botanical component, I formulate relationships among plant identity, harvested organs, cultivation conditions, phytochemical composition, extraction efficiency, and analytical quality. These relationships provide a basis for investigating how biological and environmental conditions influence medicinal-compound availability. My B-PhytoPharma research encompasses artemisinin, curcumin, epigallocatechin gallate (EGCG), resveratrol, berberine, and St John's wort, alongside medicinal plants including ashwagandha (Withania somnifera), Ginkgo biloba, Panax ginseng, milk thistle (Silybum marianum), ginger (Zingiber officinale), and Taxus species associated with paclitaxel biotechnology. These compounds and botanical resources provide complementary examples spanning phytochemical biosynthesis, metabolic regulation, inflammatory signalling, oxidative stress, pharmacokinetic interactions, and pharmaceutical applications. I investigate artemisinin biosynthesis in Artemisia annua through biochemical precursor-pool modelling. Berberine is incorporated through my BVidAL computational research involving glucose–insulin dynamics and AMPK-linked metabolic regulation. Curcumin and EGCG provide pathway-oriented examples involving inflammatory and oxidative-stress mechanisms, while St John's wort illustrates herb–drug interactions and altered metabolic clearance. Additional botanical catalogs support systematic phytochemical and medicinal-plant characterization. I further examine reproducible mathematical demonstrations. A normalized six-pool artemisinin-pathway calculation conserves modelled mass and produces a terminal-pool value of approximately 0.674452 at dimensionless time 48. A nanocarrier release-and-clearance calculation produces a normalized concentration peak of approximately 0.217153 at time 5.090504. An illustrative induced-clearance model produces an exposure ratio of approximately 0.571429. Independent calculations additionally examine selected F3 differentiation and F4 numerical identities. These results characterize explicitly specified computational models under synthetic parameter conditions.
The nano-drug delivery component provides mathematical relationships for drug loading, controlled release, transport, clearance, and exposure, supporting prospective investigations involving plant-derived pharmaceutical compounds. The principal contribution is the Bansal B-PhytoPharma Framework, which connects medicinal-plant biotechnology, phytochemical biosynthesis, molecular pharmacology, and nano-drug delivery through a unified, mechanism-resolved mathematical research architecture. I discuss its governing equations, computational investigations, classical-model relationships, and applications to plant biology, natural-product biotechnology, and pharmaceutical research.
Speaker
About the speaker
